Subtype
Prostate Adenocarcinoma
CI-CAN-00003766PRADExplore in graph →
133 active trials1 approved drugs3 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003766PRADExplore in graph →
Clinical trials
433 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (71)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02853097 | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | terminated | — | 7 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT04377152 | Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT03404648 | Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI | completed | Phase 3 | 19 | Mayo ClinicOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 2 | University of California, DavisOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer(CTC-STOP) | terminated | Phase 3 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT02175212 | Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer(AADLPC) | completed | Phase 3 | 362 | Fundación de Investigación Biomédica - Hospital Universitario de La PrincesaOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04399824 | Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2020 | clinicaltrials |
| NCT03780023 | CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients | completed | — | 5 | University of California, DavisOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04586543 | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | unknown | Phase 2 | 110 | László MangelOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02472275 | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | completed | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02228265 | Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | completed | — | 41 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT03504995 | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer. | completed | N/A | 10 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT02597894 | Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | terminated | Phase 2 | 57 | University of California, San FranciscoOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT01664130 | High-Dose Stereotactic Radiation for Prostate Cancer | completed | N/A | 35 | Case Comprehensive Cancer CenterOTHER | 1 | May 21, 2020 | clinicaltrials |
| NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | completed | Phase 1 | 23 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT01787331 | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer | completed | Phase 2 | 21 | University of California, San FranciscoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT00937768 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | terminated | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00450749 | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2019 | clinicaltrials |
| NCT02470910 | Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning | completed | N/A | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | terminated | Phase 2 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01126879 | Genistein in Treating Patients With Prostate Cancer | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01737151 | Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer | terminated | N/A | 19 | Virginia Commonwealth UniversityOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT03077659 | Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer | completed | Phase 2 | 16 | NanOlogy, LLCINDUSTRY | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01682772 | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer(TOPARP) | unknown | Phase 2 | 148 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 15, 2019 | clinicaltrials |
| NCT03451812 | Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer(PCAPETMR) | unknown | — | 120 | Chang Gung Memorial HospitalOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01028885 | MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate | completed | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT04031378 | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer | unknown | Phase 2 | 100 | Fundacao ChampalimaudOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT01117935 | Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer | completed | N/A | 55 | Virginia Commonwealth UniversityOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT03255135 | Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes. | unknown | N/A | 130 | Hospital de Transplante Doutor Euryclides de Jesus ZerbiniOTHER | 1 | Jun 27, 2019 | clinicaltrials |
| NCT03996993 | Defining Recurrent Disease With Axumin™ | unknown | — | 20 | Cancer Center of IrvineOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT01026623 | Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03034070 | Whole-Body 3D T1-weighted MR Imaging Anatomical Sequences: GE mDixon vs FSE (View) Approaches in Prostate Cancer.(TFE-TVE) | completed | N/A | 30 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | May 10, 2019 | clinicaltrials |
| NCT01927627 | Enzalutamide in Patients With High-risk Prostate Cancer | completed | Phase 2 | 42 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01530269 | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma | completed | Phase 2 | 300 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00570700 | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | completed | Phase 2 | 38 | University of California, IrvineOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01094288 | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03147196 | Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 22, 2019 | clinicaltrials |
| NCT01731912 | Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer | completed | N/A | 16 | University of WashingtonOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT01148069 | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers(TARGET) | completed | Phase 2 | 63 | Rennes University HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01832259 | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | completed | Phase 2 | 30 | University of UtahOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | Dec 4, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2021source: clinicaltrials